Indolent B-cell Non-Hodgkin’s Lymphoma
Conditions
Sponsors
GlaxoSmithKline Research and Development Limited
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Small lymphocytic, lymphoplasmacytic, marginal zone lymphoma and follicular lymphoma (FL) grades; 1, 2 and 3A defined according to WHO guidelines: • Tumor verified to be CD20+ positive from a previous or current lymph node biopsy • CT imaging in screening phase (based on local evaluation) showing 2 or more clearly demarcated lesions with a largest diameter = 1.5 cm, or 1 clearly demarcated lesion with a largest diameter = 2.0 cm. CT imaging performed at screening as baseline image 2. Indolent B-cell NHL that remains stable or unresponsive during or within 6 months of treatment with rituximab or a rituximab-containing regimen: • Maintaining stable disease or failure to achieve PR to rituximab-based therapy. (CT imaging will support this finding, and will be performed at least 60 days after the last dose of rituximab-based therapy) or, • Disease progression while on rituximab-based therapy (e.g., includes 4 weekly courses of rituximab given at 6-month intervals [Hainsworth, 2005]) or, • Disease progression in subjects with stable disease or better response to rituximab-based therapy =65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Grade 3b follicular lymphoma or evidence that the indolent lymphoma has transformed to aggressive lymphoma as verified by biopsy confirmation [e.g. constitutional symptoms, poor performance status, fast growing tumor or increasing lactate dehydrogenase (LDH) level] 2. Previous allogeneic stem cell transplant 3. Previous autologous stem cell transplant, fludarabine therapy, or radioimmunotherapy in the last 6 months 4. Previous external beam radiation therapy to the pelvis. Previous external beam radiation therapy for bony disease to the cranium, mediastinum, and axilla or to more than 3 vertebral bodies 5. High dose steroids = 100 mg prednisone/day (or equivalent) for 7 consecutive days, given as concomitant medication, within 3 months prior to randomization. No more than 10 mg prednisone daily at the time of randomization 6. Prior bendamustine treatment within 1 year of randomization not resulting in a CR or PR for at least 6 months 7. Prior treatment with anti-CD20 monoclonal antibody, if 1st dose was administered within 60 days prior to randomization. Prior use of any monoclonal antibody (other than anti-CD20) within 3 months prior to randomization. 8. Known CNS involvement of indolent lymphoma 9. Other past or current malignancy. Subjects who have been free of malignancy for at least 5 years, or have a history of definitively treated non-melanoma skin cancer, or successfully treated in situ carcinoma, are eligible* 10. Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis, and active Hepatitis C 11. Clinically significant cardiac disease including unstable angina, acute myocardial infarction within 6 months from Visit 1, congestive heart failure, and arrhythmia requiring therapy, with the exception of extrasystoles or minor conduction abnormalities 12. History of significant cerebrovascular disease or event with significant symptoms or sequelae 13. Significant concurrent, uncontrolled medical condition that in the opinion of the investigator or GSK medical Monitor contraindicates participation this study 14. Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HB DNA test will be performed and if positive the subject will be excluded** 15. Current active liver or biliary disease (subjects with Gilbert’s syndrome or asymptomatic gallstones, liver metastases related to indolent NHL or otherwise stable chronic liver disease per investigator assessment, are eligible) 16. Known HIV positive 17. Screening laboratory values: • platelets 1.5 times the institution’s upper limit of normal (ULN); subjects with a serum creatinine > 1.5 ULN will be eligible if the calculated creatinine clearance [Cockcroft, 1976] or creatinine clearance from a 24
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Secondary Objective: • To establish overall response rate, overall survival, time to and duration of response, and time to progression in subjects treated with ofatumumab (O) and bendamustine (B) combination therapy to those treated with bendamustine monotherapy • To evaluate and compare the safety and tolerability in subjects treated with O and B combination therapy to those treated with B alone • To evaluate ofatumumab pharmacokinetics when given with bendamustine • To evaluate and compare two treatment arms with respect to changes in subjects’ health-related quality of life • To evaluate and compare prognostic markers and their correlation with clinical responses in subjects treated with O and B compared to those treated with B monotherapy (i.e. ALC, FcR gamma 3, HACA) • To evaluate overall response rate to optional O monotherapy in subjects who are unresponsive to rituximab during or within 6 months of a rituximab-containing regimen who progress during or following single-agent bendamustine ;Main Objective: • To establish effectiveness of ofatumumab in combination with bendamustine in patients with indolent B-cell NHL disease relapsed after rituximab therapy;Primary end point(s): • Progression-free survival, defined as the time interval between randomization and disease progression or death | — |
Countries
Austria, Belgium, France, Germany, Greece, Italy, Poland, Slovakia, United Kingdom
Outcome results
None listed